1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

US FDA’s Role In Artificial Intelligence/Machine Learning Development Is ‘Convener,’ Califf Says

 
• By Derrick Gingery

Speaking at the Consumer Electronics Show, FDA commissioner says agency and industry must work together to understand AI/ML and continuously assess the algorithms for efficacy.

Artificial intelligence
Califf said AI algorithm assessment needs to be continuous. • Source: Shutterstock

Robert Califf sees the US Food and Drug Administration learning about artificial intelligence along with industry and expects the agency will need outside help regulating the systems.

Hundreds of products using AI have been approved by the agency. But they have so-called closed algorithms, which cannot change...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

EMA Unveils AI Tool That Improves Pharmacovigilance Signal Detection

 
• By Eliza Slawther

The European Medicines Agency is using artificial intelligence (AI) to screen scientific literature for safety signals and is also developing guidance for manufacturers on using AI in pharmacovigilance.

Small Country, Big Voice: Ireland’s Presidency Could Impact EU Pharma Policy

 
• By Francesca Bruce

Ireland, which according to industry experts has an “outsized” voice in representing the pharmaceutical sector, is set to take over the presidency of the Council of the European Union next summer.

US FDA May Ask Sponsors To Share Data To Help Train AI

 
• By Michael McCaughan

The US FDA may ask sponsors for permission to train AI models using data from new drug applications. Alternatives to animal testing could be a test case.

More To Be Done In Biopharma If Korea Is To Achieve Govt AI Vision

 
• By Jung Won Shin

Experts discussed challenges and requirements around adoption of AI and big data tools in South Korea's biopharma sector at a recent forum in Seoul, amid a broader push towards an AI-powered economy by the country's new government.

More from Advanced Technologies

US FDA Review Teams Face ‘Herculean’ Shift to Two-Month Timelines With New Voucher

 
• By Sue Sutter

The FDA is talking with cell and gene therapy staff about the importance of review timeline alignment for products accepted into the Commissioner’s National Priority Voucher program, CBER’s Katherine Szarama said.

Regenerative Medicine Expedited Pathways Need CMC To Keep Pace With Clinical Development

 
• By Sue Sutter

Sponsors may need to pursue more rapid CMC development to accommodate the faster pace of the clinical program, the FDA said in a new expedited pathways guidance, which also addresses product changes after RMAT designation and the use of real-world evidence to confirm clinical benefit.

Small Country, Big Voice: Ireland’s Presidency Could Impact EU Pharma Policy

 
• By Francesca Bruce

Ireland, which according to industry experts has an “outsized” voice in representing the pharmaceutical sector, is set to take over the presidency of the Council of the European Union next summer.